Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: GlobeNewswire
- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced the appointment of Erick J. Lucera, as chief financial officer (CFO) of Dyne, effective March 31, 2025. Mr. Lucera brings more than thirty years of financial, operational and investment experience in the life science industry to Dyne and will be instrumental in helping the company advance two late-stage clinical programs toward potential regulatory approvals. “Erick’s
Read more
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.MarketBeat
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial OfficerGlobeNewswire
- Dyne Therapeutics appoints Erick Lucera as CFO [Seeking Alpha]Seeking Alpha
- Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.MarketBeat
DYN
Earnings
- 2/27/25 - Beat
DYN
Sec Filings
- 4/1/25 - Form 4
- 4/1/25 - Form 3
- 3/27/25 - Form S-8
- DYN's page on the SEC website